Anchiano Therapeutics is an Israel based pivotal-stage biopharmaceutical company.
Anchiano is focused on the discovery, development, and commercialization of novel therapies to treat cancer in areas of unmet need. The company focuses on the development of clinical therapies for the treatment for non-muscle-invasive bladder cancer, advanced malignant neoplasms, metastatic lung cancer and metastatic liver cancer. The company is currently advancing its drug development programs, including the initiation of a pivotal trial of the company’s first-in-class and first-of-its-kind gene therapy in development for treatment of bladder cancer.
Original IPO: 2006
Arc investment: 2018
Anchiano Therapeutics Ltd. announced it has elected to hold its 2020 Annual General Meeting of Shareholders as a virtual meeting due to the ongoing public health concerns related to the coronavirus pandemic.